Google
LBRX 株価分析 — LB Pharmaceuticals Inc Common Stock (Healthcare >> Biotechnology)
LBRX に関するよくある質問
LBRXのROE（自己資本利益率）は？
LB Pharmaceuticals Inc Common StockのROEは-10.34%です。
LBRXの配当利回りは？
LB Pharmaceuticals Inc Common Stockの配当利回りは0.00%です。
LBRXの品質スコア（Quality Score）は？
当社のAIはLBRXの総合財務品質を100点中54点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
LBRXは今が買い時ですか？
当社AIのタイミングスコアは100点中91点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
LBRXはどのセクターに属しますか？
LB Pharmaceuticals Inc Common StockはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
LBRX AI Analysis Summary
Our AI summary for LBRX: LB Pharmaceuticals Inc Common Stock (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -10.34%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 45.00
Price
2.16
(5.04%)
Day Change
|
|
|---|
LBRX, ファンダメンタルスコアはnot quite good ( ファンダメンタル = 54) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
47% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 45.00 |
| PBV / Sector |
3.24 / 44,022.72
|
| Earning Per Share | -1.43 |
| PE / Sector |
N/A / 19.17
|
| PEG or PE/Growth / Sector |
N/A / 1.24
|
| Average 1M Daily Value |
13.19 M
GREAT
|
| Average 1W Daily Value |
24.92 M
GREAT
|
| Timing Factors |
|
85% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
8% |
| 登録情報 |
| Analyze Date | 2026-08-05 08:00:28 |
| Symbol | LBRX |
| Name | LB PHARMACEUTICALS INC COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 28.68 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,228.51 / 9,586.08 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: One Pennsylvania Plaza, New York, NY, United States, 10119
Phone: 212 605 0300
Website: https://lbpharma.us
Sector: Healthcare >> Biotechnology
Description: LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
